Stock page
Shield Therapeutics PLC (SHIEF)
Shield Therapeutics PLC is a commercial stage specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals that address areas of high unmet medical need. The company's operating segments are based on key products including PT20 and Feraccru, involves development and commercialisation of the Group's main Feraccru product, and PT20 is used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from the Feraccru segment.
Quote snapshot
$0.113
Daily change: —
ExchangeOTCPK
Updated2026-05-09T04:11:23.954175Z
Price chart
Price history
| Name |
|---|
| Revenue |
| Cost Of Goods Sold |
| Gross Profit |
| Gross Margin % |
| Research Development |
| Selling General Admin Expense |
| Depreciation Depletion Amortization |
| Other Operating Expense |
| Total Operating Expense |
| Operating Income |
| Operating Margin |
| Interest Income |
| Interest Expense |
| Other Income Expense |
| Other Income Minority Interest |
| Other Net Income Loss |
| Ebit |
| Ebitda |
| Ebitda Margin |
| Pretax Income |
| Tax Provision |
| Tax Rate |
| Net Income Continuing Operations |
| Net Income Discontinued Operations |
| Net Income |
| Net Income Including Noncontrolling Interests |
| Is Preferred Dividends |
| Shares Outstanding |
| Eps Basic |
| Eps Diluted |
| Net Margin |
SEC filings
Latest 10-K filing table
| Date | Form | Accession | Link |
|---|